Compare DexCom, Inc. (DXCM) vs Huntington Ingalls Industries Inc (HII) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

HII trades at $272.70, down 2.61% on the day, amid a bearish technical signal. The stock shows solid fundamentals with a P/E of 18.05 and consistent earnings beats in recent quarters, including Q1 2026 EPS of $3.79 versus $3.70 expected. Recent news highlights progress in shipbuilding contracts and expansion in unmanned systems, supporting revenue stability.

The outlook is mixed: analyst consensus is a Buy with a $354.50 price target, implying significant upside, but technical indicators signal near-term pressure. Key risks include execution on defense contracts and macroeconomic impacts on government spending. The stock presents a value opportunity for patient investors given its fundamentals versus current price.